Thursday, January 10, 2013

Partnerships in Clinical Trials Session Spotlight: The Key to Connectivity: Opportunities for Disruptive Innovation in Clinical Trials

Pharma is actively redefining what they consider competitive, and creating entirely new models for collaboration be it across companies, with patient organizations, with payers, with academic centers. That does not mean it is easy to overcome change! Today's featured session is a panel of disruptive innovators will push our audience to transform clinical trial practices, enhance current business models by unconventional means and leverage best practices to enable unprecedented connectivity with patients and researchers.

This year's Partnerships in Clinical Trails will take place April 21-24, 2013 in Orlando, Florida.  For more information on this event and the rest of the program, download the agenda.  If you'd like to join us, as a reader of this blog, when you register to join us and mention code XP1800BLOG, you'll save 15% off the standard rate!

Moderator Craig Lipset
Featured Session: The Key to Connectivity: Opportunities for Disruptive Innovation in Clinical Trials

Featured Speakers: Craig H. Lipset, Head of Clinical Innovation, Pfizer, Moderator
Eric Topol, Director, Scripps Translational Science Institute
James Heywood, Co-founder, PatientsLikeMe

About the session: The pharmaceutical industry is in the midst of an unprecedented renaissance of openness and collaboration. As the current business models and practices unravel, pharmaceutical executives are ready to re-invent the clinical trial process. Barriers have been broken with the use of cutting-edge technology, strategic alliance formation and the early stages of increased transparency. But, is this enough to push drug development to where it needs to be? Our panel of disruptive innovators will push you to transform clinical trial practices, enhance current business models by unconventional means and leverage best practices of key leaders in healthcare to use technology and enable unprecedented connectivity with patients and researchers.




No comments: